[Metabolic effects of delta-sleep inducing peptide during physiological aging of the organism].
Bondarenko. T I TI; Maĭboroda. E A EA; Mikhaleva. I I II; Prudchenko. I A IA
Key Findings
- Monthly sub‑cutaneous DSIP (10 µg/100 g) for five days improved age‑related carbohydrate metabolism in rats, lowering glycosylated hemoglobin.
- DSIP reduced total serum lipids, total cholesterol, and the atherogenicity index while raising HDL‑cholesterol.
- The effects were observed across a wide age range (2‑24 months), suggesting potential anti‑aging metabolic benefits in this animal model.
Practical Outcomes
- For biohackers, the study hints that DSIP might influence blood sugar and lipid profiles, but it’s only been shown in rats and not in humans. Until human trials exist, there’s no reliable dosage or safety data to apply this to personal protocols. Use this as a cue to watch for future human research rather than a direct supplement recommendation.
Summary
In rats, giving delta‑sleep inducing peptide (DSIP) under the skin once a month for five days helped keep blood sugar and cholesterol levels healthier as they got older. The treated rats showed lower blood sugar markers, less total fat and cholesterol in the blood, and higher good (HDL) cholesterol.
Abstract
Subcutaneous injection of delta-sleep inducing peptide (DSIP) to postnatal rats (aged from 2 to 24 months) during 5 consecutive days every months at a dose of 10 microg/100 g body weight favors normalization of the age-related changes in carbohydrate metabolism and shows hypoglycemic effect, as manifested by a decrease in the level of glycosylated hemoglobin in erythrocytes of test rats. The administration of DSIP in postnatal rats of different age also led to a decrease in serum total lipid level, total cholesterol level, and atherogenicity index and an increase in the level of high-density lipoprotein cholesterol.
Study Information
pubmed
2013